Company intelligence / Profile preview

Fimbrion Therapeutics

Saint Louis, Missouri, United Statesfimbrion.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Fimbrion has an oral antibacterial co-developed with GSK that has entered Phase I clinical trials. The company is also developing novel therapeutics to combat tuberculosis with Phase II SBIR funding.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule drugChemical drugs
Industry: Biotech

Drug pipeline

1 asset

QcrB inhibitor (Fimbrion Therapeutics)

Preclinical

Partnerships

GSK Plc

Beyond the preview

Go deeper on Fimbrion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fimbrion Therapeutics.

Explore the full profile